Alan Askenase, MD
Cardiovascular Disease · Philadelphia, PANPI 1033141320
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 50.4% of the total. 2025 is the largest year on record at $140, more than ten times the $12 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in PA, where the typical reported total is $1,447.
Across 7 payments — averaging $39.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$140
- Boston Scientific$45
- Impulse Dynamics (USA) Inc.$31
- E.r. Squibb & Sons, L.L.C.$26
- W. L. Gore & Associates, Inc.$19
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$18
What the payments were for
- Food & beverage$278100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 1 | $140 |
| Boston Scientific | 1 | $45 |
| Impulse Dynamics (USA) Inc. | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
How this compares
$278 in reported general payments places this provider in the 20th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 200 | $251,049 |
| XareltoRivaroxaban | 96 | $133,270 |
| EntrestoSacubitril/Valsartan | 55 | $83,401 |
| Repatha SureclickEvolocumab | 46 | $36,838 |
| MultaqDronedarone Hcl | 14 | $18,841 |
| Icosapent Ethyl | 21 | $9,421 |
| Praluent PenAlirocumab | 17 | $9,310 |
| Metoprolol Succinate | 516 | $8,661 |
| Atorvastatin Calcium | 423 | $5,648 |
| Rosuvastatin Calcium | 201 | $4,419 |
| Losartan Potassium | 247 | $3,106 |
| Amlodipine Besylate | 342 | $2,730 |
| Valsartan | 41 | $2,568 |
| Ranolazine ErRanolazine | 22 | $2,448 |
| Ezetimibe | 84 | $1,962 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.